Benitec Net Tangible Assets from 2010 to 2026
| BNTC Stock | USD 12.41 0.18 1.43% |
Net Tangible Assets | First Reported 2014-06-30 | Previous Quarter 9 M | Current Value 202 K | Quarterly Volatility 7.6 M |
Check Benitec Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Benitec Biopharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 59.3 K, Interest Expense of 1.1 M or Selling General Administrative of 28.3 M, as well as many indicators such as Price To Sales Ratio of 64.14, Dividend Yield of 0.0012 or PTB Ratio of 6.36. Benitec financial statements analysis is a perfect complement when working with Benitec Biopharma Valuation or Volatility modules.
Benitec | Net Tangible Assets | Build AI portfolio with Benitec Stock |
Analyzing Benitec Biopharma's Net Tangible Assets over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Tangible Assets has evolved provides context for assessing Benitec Biopharma's current valuation and future prospects.
Latest Benitec Biopharma's Net Tangible Assets Growth Pattern
Below is the plot of the Net Tangible Assets of Benitec Biopharma Ltd over the last few years. It is the total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company. Benitec Biopharma's Net Tangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Benitec Biopharma's overall financial position and show how it may be relating to other accounts over time.
| Net Tangible Assets | 10 Years Trend |
|
Net Tangible Assets |
| Timeline |
Benitec Net Tangible Assets Regression Statistics
| Arithmetic Mean | 15,431,849 | |
| Geometric Mean | 4,846,164 | |
| Coefficient Of Variation | 84.93 | |
| Mean Deviation | 11,052,051 | |
| Median | 18,405,920 | |
| Standard Deviation | 13,105,596 | |
| Sample Variance | 171.8T | |
| Range | 33.4M | |
| R-Value | (0.94) | |
| Mean Square Error | 20T | |
| R-Squared | 0.89 | |
| Slope | (2,449,432) | |
| Total Sum of Squares | 2748.1T |
Benitec Net Tangible Assets History
About Benitec Biopharma Financial Statements
Benitec Biopharma stakeholders use historical fundamental indicators, such as Benitec Biopharma's Net Tangible Assets, to determine how well the company is positioned to perform in the future. Although Benitec Biopharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Benitec Biopharma's assets and liabilities are reflected in the revenues and expenses on Benitec Biopharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Benitec Biopharma Ltd. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Tangible Assets | 181.8 K | 172.7 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Benitec Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Benitec Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Benitec Biopharma Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Benitec Biopharma Ltd Stock:Check out the analysis of Benitec Biopharma Correlation against competitors. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Will Biotechnology sector continue expanding? Could Benitec diversify its offerings? Factors like these will boost the valuation of Benitec Biopharma. Projected growth potential of Benitec fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Benitec Biopharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.09) | Revenue Per Share | Quarterly Revenue Growth 0.125 | Return On Assets | Return On Equity |
The market value of Benitec Biopharma is measured differently than its book value, which is the value of Benitec that is recorded on the company's balance sheet. Investors also form their own opinion of Benitec Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Benitec Biopharma's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Benitec Biopharma's market value can be influenced by many factors that don't directly affect Benitec Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Benitec Biopharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Benitec Biopharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Benitec Biopharma's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.